(412 days)
Not an FDA-regulated device
Not Found
No
The summary describes a standard microdilution panel for antimicrobial susceptibility testing and does not mention any AI or ML components. The reading is visual and the performance evaluation is based on essential agreement with a reference panel.
No
The device is used to determine the antimicrobial susceptibility of bacteria, which is a diagnostic function, not a therapeutic one.
Yes
The device determines bacterial antimicrobial agent susceptibility, which is a diagnostic function used to guide treatment decisions.
No
The device description explicitly states "Microdilution Minimum Inhibitory Concentration (MIC) Panels," which are physical laboratory panels used for testing. The summary also describes incubation and visual reading, indicating a hardware component is involved in the testing process.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is "To determine bacterial antimicrobial agent susceptibility." This is a classic example of an in vitro diagnostic test, as it involves analyzing a biological sample (bacteria) outside of the body to provide information about a patient's condition (susceptibility to antibiotics).
- Device Description: The device is described as "Microdilution Minimum Inhibitory Concentration (MIC) Panels." MIC panels are a common type of IVD used in microbiology laboratories to determine the lowest concentration of an antimicrobial agent that inhibits the visible growth of a microorganism.
- Sample Type: The test is performed on bacterial isolates, which are biological samples taken from a patient.
- Purpose: The results of the test are used to guide treatment decisions for patients with bacterial infections.
The information provided clearly indicates that this device is used to perform a diagnostic test on biological samples in a laboratory setting, which aligns with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
To determine bacterial antimicrobial agent susceptibility
For use with aerobic non-enterococcal streptococci including S. pneumoniae
The MicroScan® MICroSTREP plus™ Panel is used to determine antimicrobial susceptibility of aerobic non-enterococcal streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20-24 hours at 35℃ +/- 1℃ in a non-CO2 incubator, and read visually according to the Package Insert.
This particular submission is for the addition of the antimicrobial AMOXICILLIN at concentrations of 0.008 - 16 mcg/ML to the test panel.
The organisms which may be used for AMOXICILLIN susceptibility testing in this panel are;
Streptococcus pneumoniae
Product codes (comma separated list FDA assigned to the subject device)
JWY
Device Description
Microdilution Minimum Inhibitory Concentration (MIC) Panels
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The proposed MicroScan® MICroSTREP plusTM Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an NCCLS frozen Reference Panel, as defined in the FDA DRAFT document "Review Criteria for Assessment of Antimicrobial Susceptibility Devices" (dated May 31, 1991).
The MICroSTREP plus™ Panel demonstrated acceptable Essential Agreement performance when compared with the frozen Reference panel.
Reproducibility testing demonstrated acceptable reproducibility and precision with each of the antimicrobial agents tested.
Quality Control testing demonstrated acceptable results for each of the antimicrobial agents tested.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement performance, Reproducibility, precision, Quality Control results.
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
NCCLS Frozen Reference Panels
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.1640 Antimicrobial susceptibility test powder.
(a)
Identification. An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
DEC - 9 1999
Dade Behring
DADE MICROSCAN INC. 1584 Enterprise Boulevard West Sacramento, CA 95691 Tel: +1 (916) 372-1900
510(k) Summary Information:
| Device Manufacturer: | Dade MicroScan Inc. |
|---|---|
| Contact name: | Sharolyn Lentsch, Regulatory Affairs Manager |
| Fax: | 916-374-3144 |
| Date prepared: | October 22, 1998 |
| Product Name: | Microdilution Minimum Inhibitory Concentration (MIC) Panels |
| Trade Name: | MicroScan® MICroSTREP plus™ Panel - Amoxicillin |
| Intended Use: | To determine bacterial antimicrobial agent susceptibility |
| Indication for Use | For use with aerobic non-enterococcal streptococci including S. pneumoniae |
| Predicate device: | NCCLS Frozen Reference Panels |
510(k) Summary:
The proposed MicroScan® MICroSTREP plusTM Panel demonstrated substantially equivalent performance with streptococcal isolates when compared with an NCCLS frozen Reference Panel, as defined in the FDA DRAFT document "Review Criteria for Assessment of Antimicrobial Susceptibility Devices" (dated May 31, 1991).
The Premarket Notification (510[k]) presents data in support of the new MICroSTREP plus™ Panel with various antimicrobial agents.
The external evaluation was conducted with fresh and stock Efficacy isolates and stock Challenge strains. The MICroSTREP plus™ Panel demonstrated acceptable Essential Agreement performance when compared with the frozen Reference panel.
Reproducibility testing demonstrated acceptable reproducibility and precision with each of the antimicrobial agents tested.
Quality Control testing demonstrated acceptable results for each of the antimicrobial agents tested.
1
Image /page/1/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features the department's name encircling a symbol. The symbol consists of three stylized human figures or shapes that are interconnected. The figures are arranged in a way that suggests movement or progress.
DEC - 9 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Trevor Wall Regulatory Affairs Manager Dade MicroScan, Inc. 1584 Enterprise Boulevard West Sacramento, California 95691
Re: K983746
Trade Name: MicroScan® MICroSTREP plus™ Panel (AMOXICILLIN) Regulatory Class: II Product Code: JWY Dated: October 1, 1999 Received: October 4, 1999
Dear Mr. Wall:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Page Ol
510(k) Number (if known): 长 98 3746
Device Name: MICroSTRED plus To pares - AMOXIC illio
Indications For Use:
The MicroScan® MICroSTREP plus™ Panel is used to determine antimicrobial susceptibility of aerobic non-enterococcal streptococci, including Streptococcus pneumoniae. After inoculation, panels are incubated for 20-24 hours at 35℃ +/- 1℃ in a non-CO2 incubator, and read visually according to the Package Insert.
This particular submission is for the addition of the antimicrobial AMOXICILLIN at concentrations of 0.008 - 16 mcg/ML to the test panel
The organisms which may be used for AMOXICILLIN susceptibility testing in this panel are;
Streptococcus pneumoniae
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Woodei Deebois
Division of Clifical Laboratory Devices 510(k) Number_198374
Prescription Use
(Per 21 CFR 801.109)
OR
Over-The-Counter Use_
(Optional Format 1-2-96) ·